45O Stock Overview
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Orgenesis Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.53 |
52 Week High | US$0.76 |
52 Week Low | US$0.42 |
Beta | 1.1 |
1 Month Change | n/a |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -85.58% |
5 Year Change | n/a |
Change since IPO | -87.92% |
Recent News & Updates
Recent updates
Shareholder Returns
45O | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | 1.8% | -1.2% |
1Y | n/a | -19.8% | 1.8% |
Return vs Industry: Insufficient data to determine how 45O performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 45O performed against the German Market.
Price Volatility
45O volatility | |
---|---|
45O Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 45O has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 45O's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 146 | Vered Caplan | orgenesis.com |
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals.
Orgenesis Inc. Fundamentals Summary
45O fundamental statistics | |
---|---|
Market cap | €16.70m |
Earnings (TTM) | -€51.65m |
Revenue (TTM) | €494.44k |
33.8x
P/S Ratio-0.3x
P/E RatioIs 45O overvalued?
See Fair Value and valuation analysisEarnings & Revenue
45O income statement (TTM) | |
---|---|
Revenue | US$530.00k |
Cost of Revenue | US$6.26m |
Gross Profit | -US$5.72m |
Other Expenses | US$49.64m |
Earnings | -US$55.36m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.63 |
Gross Margin | -1,080.19% |
Net Profit Margin | -10,445.47% |
Debt/Equity Ratio | -106.2% |
How did 45O perform over the long term?
See historical performance and comparison